Targeted ultrasound therapy offers a less invasive prostate cancer treatment designed to minimize disruption to daily life.

Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces that its partner Asieris Pharmaceuticals (SSE: 688176) communicated today that its core product APL-1702 (trade name: CEVIRA®), has ...

Wisdom Bioscience, Inc., a biotechnology company pioneering non-invasive oral cancer diagnostics, today announced the formation of its Scientific Advisory Board (SAB) following the close of an initial ...

CEO Dr. Raza Bokhari talked with Proactive about the company’s newly reported topline Phase 2 results for its microneedle array patch technology targeting basal cell carcinoma, a common form of ...

(Yicai) March 4 -- Shares of Asieris Pharmaceuticals soared by their daily trading limit after China granted the drugmaker marketing approval for Cevira, the world’s first non-surgical, non-invasive ...

A recent breakthrough study highlights how a simple at-home urine test could accurately detect prostate cancer. Researchers from Vanderbilt University and the University of Michigan suggest this ...

Photonic crystal sensor shows over 91% accuracy for cervical cancer screening, maintaining performance across varied ...

On Monday, members of the Lebanon City Fire Department were screen for esophageal cancer. It was conducted by Lucid ...

The interim analysis of the BCG-Unresponsive cohort includes 35 evaluable participants, of whom, 22 were evaluable at six months and 15 were evaluable at 12 months as of a January 28, 2026 data cutoff ...